Antimigraine activity of Ficus deltoidea jack aqueous extract in mice and its possible mechanisms
Migraine is a disabling headache disorder characterized by throbbing headache and associated with various symptoms namely nausea, vomiting and heightened sensitivity to touch and smell. Ficus deltoidea is an herbaceous plant used traditionally in treating pain and headache. As phytomedicine produ...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | http://psasir.upm.edu.my/id/eprint/90464/1/FPSK%28p%29%202020%203%20-%20IR.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Migraine is a disabling headache disorder characterized by throbbing headache
and associated with various symptoms namely nausea, vomiting and heightened
sensitivity to touch and smell. Ficus deltoidea is an herbaceous plant used
traditionally in treating pain and headache. As phytomedicine produce alternative
therapeutic strategies for migraine pain, the aim of this study is to evaluate the
antimigraine properties of Ficus deltoidea (var Trengganuensis) aqueous extract
(FDA) and its possible mechanisms. In nonspecific antimigraine study, using
animal model of nociception, administration of FDA produced significant
antinociceptive effect in acetic acid-induced abdominal writhing test, early and
late phase of formalin test and in the hot plate test. In specific antimigraine study,
nitroglycerin (NTG)-induced migraine model was used. It is the most studied and
well accepted model in antimigraine drug testing. Preliminary tests were done
verifying and optimizing the use of this model. The effect of FDA was tested in
NTG-induced hyperalgesia using formalin and hot plate test. It was found that
FDA produced significant inhibition in both early and late phase of formalin test
and significant increase in respond latency in hot plate test. In addition, treatment
with FDA significantly reduced the NTG-induced c-fos expression in trigeminal
nucleus caudalis (TNC), a relay center in migraine. This study also explored the
mechanism of FDA through peripheral and central sensitization, and involvement
of serotonergic and dopaminergic pathways. The involvement of FDA in
peripheral sensitization was done using kainic acid-induced hyperalgesia in hot
plate test, showing significant increase in response latency in group receiving
FDA compared to control. In study of central sensitization, using NTG-induced
mechanical allodynia in von Frey test, FDA group produced significant
improvement in paw withdrawal threshold compared to control. Studies on
serotonergic and dopaminergic systems involvement was done by studying the
effect of FDA on 5-hydroxytryptophan(l-5-HTP)-induced serotonin syndrome and
apomorphine-induced climbing behavior. Results showed FDA significantly
inhibited l-5-HTP-induced serotonin syndrome and apomorphine-induced
climbing activity. In addition, FDA significantly inhibited NTG induced plasma CGRP using ELISA. These findings suggested that FDA possessed antimigraine
activity through inhibition of peripheral and central sensitization with possibility
of involvement of dopaminergic and serotonergic mechanism and CGRP
inhibition. |
|---|